GlassScriptPhysician profile
David J Mapes
NPI 1427428010
$11,099.95
in general payments reported to CMS, 2019-2025
22 companies · $6,479 in 2025
The $6,479 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,019 · 2023: $2,301 · 2024: $1,301 · 2025: $6,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,690 · Travel and Lodging: $2,410 · Consulting Fee: $1,800 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,689.57 |
| Travel and Lodging | $2,409.83 |
| Consulting Fee | $1,800.00 |
| Education | $181.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $4,888.05 | 2023-2025 | Zoryve |
| Abbvie INC. | $1,660.68 | 2022-2025 | |
| Incyte Corporation | $963.84 | 2022-2025 | Opzelura, Opzelura, Iclusig |
| Janssen Biotech, INC. | $852.10 | 2023-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $645.73 | 2023-2025 | |
| Genzyme Corporation | $452.08 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $244.68 | 2023-2025 | Sotyktu |
| Ucb, INC. | $229.82 | 2022-2025 | Bimzelx, Cimzia |
| Amgen INC. | $217.35 | 2023-2025 | Otezla, Otezla |
| Janssen Scientific Affairs, LLC | $205.36 | 2022 | |
| Leo Pharma INC. | $176.96 | 2022-2025 | Anzupgo, Adbry |
| Lilly USA, LLC | $110.54 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $89.00 | 2024-2025 | Nemluvio |
| Pfizer INC. | $81.51 | 2022-2023 | |
| Dermavant Sciences, INC. | $76.65 | 2023-2024 | Vtama |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $48.96 | 2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.76 | 2023 | Spevigo, Cyltezo |
| Sun Pharmaceutical Industries INC. | $30.55 | 2025 | |
| Organogenesis INC. | $24.54 | 2022 | |
| Verrica Pharmaceuticals INC. | $21.35 | 2024 | Ycanth |
| Organon LLC | $16.60 | 2025 | |
| Smith+Nephew, INC. | $15.84 | 2024 | Iodosorb Ointment 40g USA, Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mapes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.